Other
Common stock, shares authorized (in shares)
Neurocrine Biosciences Common stock, shares authorized (in shares) remained flat by 0.0% to $220M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $220M to $220M. Over 5 years (FY 2020 to FY 2025), Common stock, shares authorized (in shares) shows relatively stable performance with a 0.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2019
Last reportedQ1 2026May 5, 2026
Metric ID:
other_common_stock_shares_authorizedHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M | $220M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
Range$220M – $220M
CAGR+0.0%
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Current Streak19+ quarters growth
Common stock, shares authorized (in shares) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's common stock, shares authorized (in shares)?
- Neurocrine Biosciences (NBIX) reported common stock, shares authorized (in shares) of $220M in Q1 2026.
- How has Neurocrine Biosciences's common stock, shares authorized (in shares) changed year-over-year?
- Neurocrine Biosciences's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $220M to $220M.
- What is the long-term trend for Neurocrine Biosciences's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $220M to $220M.